dr. kelly on the rationale for the checkmate-577 trial in esophageal/gej cancer
Published 3 years ago • 451 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
3:12
nivolumab for perioperative esophageal and gastroesophageal cancer: checkmate 577
-
4:14
adjuvant nivolumab in patients with resected esophageal or gej cancer (checkmate 577)
-
1:31
dr. ko discusses the checkmate-577 trial
-
13:47
checkmate 577 - is nivolumab adjuvant the standard of care in esophagus and gej?
-
1:21
dr. shah on the rationale for the keynote-590 trial in esophageal carcinoma
-
1:07:28
drs. kelly & molena discuss new esophageal updates: https://bit.ly/2021-esophageal
-
5:18
checkmate577: nivolumab in ec/gejc
-
1:02:35
1.oesophageal endoscopy – an unusual finding 2.haemochromatosis - prof m hale & dr v lala
-
8:16
nivolumab for oesophageal cancer following chemoradiation therapy
-
1:29
dr. kelly on the toxicity profile in checkmate-227 in nsclc
-
9:10
adjuvant nivolumab in resected oesophageal or goj cancer following chemo
-
1:43
dr. chau on checkmate577 study in esophageal/gej cancer
-
2:19
jaffer ajani, md, shares thoughts on the checkmate 577 study presented at esmo 2020
-
3:42
geoffrey y. ku, md, provides perspective on the checkmate-577 clinical study presented at esmo 2020
-
6:31
checkmate 649 biomarker analyses of nivo ipi vs chemo for patients with gc/gejc/eac
-
10:45
new data on adjuvant treatment of esophageal cancer
-
1:44
dr. mamdani on the need for novel therapies in locally advanced esophageal/gej adenocarcinoma
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc
-
1:44
checkmate 649: nivolumab and chemotherapy or ipilimumab in gc/gejc/eac